Phase 1 Plasma Clinical Trials
34 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 34 trials
Recruiting
Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Acute Myeloid LeukemiaMyelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm
Dana-Farber Cancer Institute72 enrolled3 locationsNCT03113643
Recruiting
Phase 1Phase 2
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Plasma Cell Myeloma Refractory
Sanofi258 enrolled26 locationsNCT04643002
Recruiting
Phase 1
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Multiple MyelomaPlasma Cell Myeloma
Robert Flavell, MD, PhD20 enrolled1 locationNCT05892393
Recruiting
Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 1Phase 2
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting
Phase 1
High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
Plasma Cell Disorder
University of Arkansas18 enrolled1 locationNCT06313502
Recruiting
Phase 1
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Non-Hodgkin LymphomaPlasmablastic LymphomaBurkitt Lymphoma+2 more
National Cancer Institute (NCI)25 enrolled1 locationNCT05389423
Recruiting
Phase 1
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
Chronic Myeloid LeukemiaMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics130 enrolled7 locationsNCT05362773
Recruiting
Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myeloid Leukemia+26 more
Fred Hutchinson Cancer Center24 enrolled1 locationNCT03326921
Recruiting
Phase 1Phase 2
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoplasmacytic Lymphoma+5 more
ModeX Therapeutics, An OPKO Health Company180 enrolled2 locationsNCT07249905
Recruiting
Phase 1
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Multiple Myeloma or Plasmacytoma
Shenzhen Geno-Immune Medical Institute10 enrolled2 locationsNCT06435910
Recruiting
Phase 1Phase 2
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Multiple MyelomaPlasmacytoma
Shenzhen Geno-Immune Medical Institute20 enrolled2 locationsNCT06429150
Recruiting
Phase 1
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma and Other Plasma Cell Neoplasms
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.15 enrolled5 locationsNCT07529782
Recruiting
Phase 1
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
City of Hope Medical Center30 enrolled1 locationNCT03710421
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Peripheral T Cell LymphomaT-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia+4 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
Plasma Cell Myeloma Refractory
Sanofi87 enrolled19 locationsNCT06630806
Recruiting
Phase 1
Study of SGR-1505 in Mature B-Cell Neoplasms
High-grade B-cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+23 more
Schrödinger, Inc.98 enrolled36 locationsNCT05544019
Recruiting
Phase 1
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaMantle Cell Lymphoma+7 more
C. Babis Andreadis36 enrolled1 locationNCT04545762
Recruiting
Phase 1Phase 2
Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
Plasma Cell Disorder
University of Maryland, Baltimore30 enrolled1 locationNCT07075510
Recruiting
Phase 1
Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
City of Hope Medical Center15 enrolled1 locationNCT05363111